Regeneron flooded with apps for Irish jobs; Cipla nabs Yemeni drug maker for $21M; Stada buys foot products;

@FiercePharma: Top-read on FP this weekend: Sanofi's Lantus empire imperiled as EU recommends Lilly, Boehringer biosimilar. Article | Follow @FiercePharma

@TracyStaton: Here's @JohnCFierce's take on the Vertex VX-809/Kalydeco PhIII, including interview with CEO Jeff Leiden. Story | Follow @TracyStaton

@EricPFierce: This Indian pharma exec understands how to attain quality production & that many of his compatriots do not. ICYMI from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: ICYMI: Vertex could snag 250 more Kalydeco patients with EMA nod. Item | Follow @CarlyHFierce

> Almost 1,500 people have applied to work at Regeneron Pharmaceuticals' ($REGN) new plant in Ireland, where it's gearing up to produce now in its pipeline. Report

> India's Cipla agreed to pay $21 million for a controlling stake in a pharma manufacturing and distribution business in Yemen. Report

> Germany's Stada says it bought a family of topical foot-care products sold under the Flexitol brand from the Australian company Lacorium Group. Report

> A U.S. appeals court upheld the dismissal of almost all claims in 68 liability lawsuits over the generic versions of the older painkillers Darvon and Darvocet. Report

> GlaxoSmithKline ($GSK) and Genmab said their blood cancer drug Arzerra flunked a late-stage trial in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Report

Medical Device News

@FierceMedDev: ICYMI: Will Medtronic deal with Covidien benefit smaller players?  exec says yes. Article | Follow @FierceMedDev

@StacyALawrence: ICYMI: FDA clears first robotic exoskeleton for spinal cord injury patients. More | Follow @StacyALawrence

@VarunSaxena2: ICYM last week's feature: Top 10 Med Tech R&D Budgets. Special Report | Follow @VarunSaxena2

@MichaelGFierce: Intersect ENT files for $80M IPO to support steroid-delivering sinus implants. FierceDrugDelivery story | Follow @MichaelGFierce

@EmilyWFierce:  OKs first wearable motorized device that helps people with spinal cord injuries walk, More from the NYT | Follow @EmilyWFierce

> Study: One-third of knee replacements are inappropriate. Article

> Device for 'smart' kegel exercises to debut soon. More

> Researchers develop a durable hydrogel for use with implantable devices. Story

Biotech News

@FierceBiotech: ICYMI Friday: Another Pfizer bid for AstraZeneca? Investors weigh in. Report | Follow @FierceBiotech

@JohnCFierce: So here's Jeff Stein's new company, Cidara--why all the hush-hush? Release | Follow @JohnCFierce

@DamianFierce: Fun with the U.K. takeover code: $ABBV's $46B bid is blocking $SHPG from shopping for itself. More | Follow @DamianFierce

@EmilyMFierce: Will Europe map the human brain faster than the U.S. can? More from Bloomberg | Follow @EmilyMFierce

> Merck takes to Europe with its promising PD-1 cancer drug. Item

> Two more biotechs roll the IPO dice as the market sputters. More

> Biotech vets sign up to launch Cidara with $32M, new drugs for fungal infections. News

CRO News

> Recipharm and CTC unite for early-stage trials. Item

> Evotec pockets a payment in its Boehringer partnership. News

> ClinicalRM teams up with an Ohio network for clinical trials. More

> Bristol-Myers enlists Duke's CRO to help it share trial data. Report

> Parexel expects to hit the $2B mark in fiscal 2015. Article

> Covance is creating an OkCupid for molecules. Story

Biotech IT News

> Survey: Firms prioritizing data security over business-boosting analysis. Story

> U.K. scales back plans for patient database as docs back major revision. Report

> NIH aiming to lower IT barriers to 3D printing in drug research. More

> Experts warn FDA Twitter guidance will silence social conversation. Item

> Bristol-Myers strikes deal with Duke to open up trial data. Story

> Europe's brain project plans grant incentives to encourage data sharing. Article

And Finally... The U.S. Justice Department is arguing for more than 8 years prison for SAC Capital portfolio manager nabbed in pharma-related insider trading probe. Report

Suggested Articles

With a brand new approval for Adakveo under its belt, Novartis Sunday flaunted an analysis showing the drug could cut patient hospitalizations by 40%.

BeiGene only just won its first Brukinsa nod in MCL. But it’s already pushing to join the CLL field, and Sunday it rolled out more data.

How long can one infusion of CAR-T drug Yescarta continue helping patients with refractory large B-cell lymphoma? Pretty long, Gilead showed Saturday.